ClinicalTrials.gg
RecruitingNCT07019350SMART-DCBUpdated Nov 24, 2025

Smart Angioplasty Research Team-Optimal Strategy for Side Branch Stenting in Coronary Bifurcation Lesion With Drug-Coated Balloon

An interventional study of Upfront DCB-based hybrid strategy and Upfront 2-stenting strategy in Coronary Artery Disease, sponsored by Samsung Medical Center. Recruiting at 3 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Coronary Artery Disease by Samsung Medical Center — 10 open to participants now, 14 under way, none of them phase 3. Coronary Artery Disease · Samsung Medical Center.

Planned enrollment
11th of 21
520 · median 520
Started
2025
with 1 other
No phase
16 of 31
5 open now
Primary completion
2030-12
later than 11 of 13 live
Registered
28th of 31
by date

Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, this one is the 11th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2025, is one of 16 with no phase, reaches primary completion later than 11 of the 13 other live ones, and was the 28th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

10 of the 31 studies in Coronary Artery Disease by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Coronary Artery Disease by Samsung Medical Center, or all of them as a file.
02

Study summary

A prospective, multi-center, open-label, randomized controlled, superiority trial. The aim of the study is to compare clinical outcomes between upfront 2-stenting strategy versus upfront drug-coated balloon (DCB)-based hybrid strategy in patients with complex coronary bifurcation with clinically relevant side branch lesions.

Read the detailed description

Among complex coronary artery lesions, percutaneous coronary intervention (PCI) for true bifurcation lesions has been challenging to perform and associated with a higher risk of mortality, unplanned repeat revascularization or stent thrombosis.15-17 Although current guidelines recommend 1-stenting with provisional side branch approach as an initial treatment strategy for the bifurcation lesions based on previous trials,11,12,18-22 there are studies that demonstrate better or similar outcomes with the upfront 2-stenting strategy.3,4,21,23 Of note, these trials that have favored upfront 2-stenting strategy have shown a tendency for better efficacy of 2-stenting as the severity of bifurcation lesions increases.3,4,21,23 Considering that the discrepancy among study results could be attributable to the complexity of true bifurcation lesions, it can be argued that 1-stenting with provisional SB approach by conventional balloon dilatation shows limitations in dealing with severely complex true bifurcation lesions.

During provisional stenting, unplanned side branch stenting is associated with worse clinical outcomes.24 In addition, SB failure occurred more frequently than main vessel failure in both 1-stenting and 2-stenting group.25 Considering these results, there have been some studies trying to demonstrate the effect of drug-coated balloon (DCB) angioplasty at side branch during the PCI for bifurcation lesions.5,26 In the most recent trial, DCB angioplasty yielded better results compared to conventional simple balloon dilatation.5 Thus, for true bifurcation lesions, upfront DCB-based hybrid strategy could serve as a good alternative treatment strategy that improves clinical outcomes for patients with complex coronary bifurcation lesion with clinically relevant side branch.

On this background, this trial sought to compare the clinical outcomes between upfront DCB-based hybrid strategy and upfront 2-stenting strategy in patients with complex coronary bifurcation with clinically relevant side branch.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Complex Coronary Bifurcation
  • Upfront 2-stenting
  • Upfront Drug-coated Balloon
  • Side Branch
  • Prognosis
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be at least 19 years of age
  • Patients with acute or chronic coronary syndrome intended for percutaneous coronary intervention (PCI)
  • Patients with de novo complex coronary bifurcation with side branch. Definition of complex coronary bifurcation with clinically relevant side branch is true bifurcation lesion (Medina 1,1,1 / 1,0,1 / 0,1,1) with side branch lesion length ≥10mm and should meet at least one of the below criteria.

    i. Left main bifurcation with side branch stenosis severity ≥70% by visual estimation ii. Non-left main bifurcation with side branch reference vessel diameter ≥2.75mm and stenosis severity ≥90% by visual estimation

  • Subject who can verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive approach and he/she or his/her legally authorized representative provides written prior to any study related procedure.

Exclusion criteria

Exclusion Criteria

  • Hemodynamically unstable condition (SBP \<90 mmHg even after administration of vasopressor, ventricular arrhythmias, or cardiogenic shock)
  • Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
  • Known significant congenital, severe valvular or cardiomyopathic (hypertrophic or dilated cardiomyopathy, or any other forms) process which could explain cardiac symptoms.
  • Severe left ventricular systolic dysfunction ( \<30%)
  • Intolerance to aspirin, clopidogrel, ticagrelor, prasugrel, or heparin.
  • Non-cardiac co-morbid conditions are present with \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  • Unwillingness or inability to comply with the procedures described in this protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
520 participants (estimated)

Study arms

  • Experimental
    Upfront DCB-based hybrid strategy

    In upfront DCB-based hybrid strategy group, stepwise provisional strategy with side branch DCB angioplasty will be performed according to the follow standardized procedural steps. In this group, provisional stenting strategy will be performed in accordance with the European Bifurcation Club (EBC) consensus. Bail-out stenting will be performed using operator's preferred technique (e.g. T, TAP, culotte) when there will be one of the following after hybrid strategy: \<TIMI 3 flow in the side branch, severe (\>90%) ostial pinching, or flow-limiting dissection.

    Other: Upfront DCB-based hybrid strategy

  • Active comparator
    Upfront 2-stenting strategy

    In upfront 2-stenting strategy group, systematic planned 2-stenting will be performed according to EBC recommendations. The stent technique will be at the discretion of the operator but could be one of culotte, DK-culotte, mini-crush, DK-crush, T or TAP.

    Other: Upfront 2-stenting strategy

Interventions

  • OtherUpfront DCB-based hybrid strategy

    In upfront DCB-based hybrid strategy group, stepwise provisional strategy with side branch DCB angioplasty will be performed according to the follow standardized procedural steps. In this group, provisional stenting strategy will be performed in accordance with the European Bifurcation Club (EBC) consensus. Bail-out stenting will be performed using operator's preferred technique (e.g. T, TAP, culotte) when there will be one of the following after hybrid strategy: \<TIMI 3 flow in the side branch, severe (\>90%) ostial pinching, or flow-limiting dissection.

  • OtherUpfront 2-stenting strategy

    In upfront 2-stenting strategy group, systematic planned 2-stenting will be performed according to EBC recommendations. The stent technique will be at the discretion of the operator but could be one of culotte, DK-culotte, mini-crush, DK-crush, T or TAP.

06

What researchers measure

Primary outcomes

  1. Major Adverse Cardiac Event (MACE)

    MACE (a composite of death, MI, clinically-driven target-vessel revascularization), according to the Academic Research Consortium (ARC) II-consensus.

    Time frame: 1 year after last patient enrollment

Secondary outcomes

  1. All-cause death

    All-cause death

    Time frame: 1 year after last patient enrollment

  2. Cardiac death

    Cardiac death

    Time frame: 1 year after last patient enrollment

  3. Any MI (myocardial infarction)

    Any MI, defined by Fourth Universal definition of M

    Time frame: 1 year after last patient enrollment

  4. Spontaneous MI (myocardial infarction)

    Spontaneous MI (myocardial infarction), defined by Fourth Universal definition of MI

    Time frame: 1 year after last patient enrollment

  5. Procedure-related MI (myocardial infarction)

    Procedure-related MI (myocardial infarction), defined by ARC II definition

    Time frame: 1 year after last patient enrollment

  6. Stent thrombosis

    Stent thrombosis, defined by ARC II definition

    Time frame: 1 year after last patient enrollment

  7. Unplanned revascularization (clinically-driven)

    Unplanned revascularization (clinically-driven)

    Time frame: 1 year after last patient enrollment

  8. Target-vessel revascularization (clinically-driven)

    Target-vessel revascularization (clinically-driven)

    Time frame: 1 year after last patient enrollment

  9. Cerebrovascular accidents (ischemic or hemorrhagic)

    Cerebrovascular accidents (ischemic or hemorrhagic)

    Time frame: 1 year after last patient enrollment

  10. Bleeding (BARC 2, 3, or 5)

    Bleeding (BARC 2, 3, or 5)

    Time frame: 1 year after last patient enrollment

  11. Seattle Angina Questionnaire (SAQ) (angina severity)

    Seattle Angina Questionnaire (SAQ) (angina severity)

    Time frame: 1 year after last patient enrollment

  12. Procedure-related complications during index procedure

    Procedure-related complications during index procedure

    Time frame: 1 year after last patient enrollment

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — After completion of primary trial report, executive committee members will have discussion about sharing the individual participant data (IPD) upon reasonable requests,

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After completion of primary trial report

Access criteria: Upon reasonable requests, executive committee members will have discussion about sharing the individual participant data (IPD).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2030, 62 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 62 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 13, 2025
StartActual
Oct 22, 2025
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07019350
Responsible party
Young Bin Song (Professor, Samsung Medical Center) — Principal investigator
First posted
Jun 13, 2025
Start date
Oct 22, 2025
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 24, 2025

Study contacts

Young Bin Song, MD, PhD
Contact
youngbin.song@gmail.com
82-2-3410-2575
Joo Myung Lee, MD, MPH, PhD
Contact
drone80@hanmail.net
82-2-3410-2575
Young Bin Song, MD, PhD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion